hrp0092p3-82 | Diabetes and Insulin | ESPE2019

Assessment of Testicular Volume by Ultrasound in Children and Adolescents with Type 1 Diabetes

Lohiya Nikhil , Khadilkar Vaman , Khadilkar Anuradha , Kinare Arun

Introduction: Poorly controlled type 1 diabetes affects the hypothalamic pituitary axis and is likely to have a negative impact on spermatogenesis and result in infertility. Further, a chronic complication of diabetes may also be angiopathy of testicular vessels. Thus, at our center for children with diabetes, testicular ultrasound evaluation is performed on adolescent boys with duration of diabetes> 2 years.Objective</strong...

hrp0092p2-38 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Skeletal Maturity and Growth in children with Type 1 Diabetes

Lohiya Nikhil , Khadilkar Anuradha , Khadilkar Vaman

Background: Type 1 diabetes (T1D) being a chronic disease is likely to affect growth in children. Bone age helps in assessing the growth of child in relation to their skeletal maturity. Skeletal maturity is delayed in chronic systemic illness.Objective: To study growth in relation to bone age and chronological age in children with T1D.Methods: Study design: Prospective observationa...

hrp0086p2-p92 | Adrenal P2 | ESPE2016

A Rare Endocrine Association of Dilated Cardiomyopathy with Congenital Adrenal Hyperplasia due to 11 Beta Hydroxylase Deficiency

Patil Prashant , Jahagirdar Rahul , Khadilkar Vaman , Seniappan Senthil

Background: Cardiomyopathy is a heterogeneous group of disorder of myocardium associated with mechanical and/or electrical dysfunction that usually exhibit inappropriate ventricular hypertrophy or dilatationleading to heart failure. Congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency is rare inherited disorder of cortisol biosynthesis, due to genetic defects of CYP11B1 gene presenting as hypertension, features of androgen excess, and peripheral precocio...

hrp0086p2-p333 | Diabetes P2 | ESPE2016

Association Between Socioeconomic Status and Glycemic Control in Type 1 Diabetes Mellitus

Patil Prashant , Giri Dinesh , Khadilkar Vaman , Seniappan Senthil

Background: Socioeconomic status (SES) is inversely associated with many chronic diseases, with disadvantaged individuals faring worse than the others. In diabetes mellitus, however, studies evaluating the relationship between SES and the glycaemic control have shown variable results.Objective and hypotheses: To understand the effect of SES on the long term glycemic control in children with type 1 diaebtes mellitus (T1DM) at a tertiary centre in India.</...

hrp0089fc10.2 | Late Breaking | ESPE2018

Efficacy and Safety of Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Results of a Randomised Open-Label, Controlled Phase 2 Trial

Savendal Lars , Rasmussen Michael , Horikawa Reiko , Khadilkar Vaman , Battelino Tadej , Saenger Paul

Background: Growth hormone deficiency (GHD) requires long-term daily injections with GH replacement therapy and is associated with considerable treatment burden by patients and caregivers. Somapacitan is a long-acting GH derivative that is being developed for once-weekly dosing in adults and children with GHD. A well-established protraction method, which is successfully in use to extend the half-life of insulin and glucagon-like peptide (GLP)-1, has been applied in developing ...

hrp0095p1-119 | Growth and Syndromes | ESPE2022

Post-hoc subgroup analysis of Asian subjects from the pivotal phase 3 study of once-weekly somatrogon vs once-daily Genotropin

Gomez Roy , Khadilkar Vaman , Shembalkar Jayashri , Chu Der-Ming , Woo Ko Cheol , Wajnrajch Michael , Wang Ronnie

Objectives: Somatrogon is a long-acting recombinant human growth hormone (GH) approved by the EMA as a once weekly treatment for children with pediatric GH deficiency (GHD). A global phase 3 study compared the efficacy and safety of once-weekly somatrogon with once-daily Genotropin in pediatric subjects with GHD. The objective of this subgroup analysis was to evaluate the efficacy and safety of once-weekly somatrogon vs once-daily Genotropin in the subset of A...